Tag: targeted therapy

1. Patients on adavosertib had both increased progression-free survival and better tumor control, as compared to patients being actively monitored only. 2. Overall survival was not affected by adavosertib as compared to active monitoring, but a subgroup analysis showed an increase in survival for patients with a left-sided primary compared...
1. The use of a type I KIT inhibitor, such as PLX9486, in combination with a type II inhibitor, such as sunitinib, was associated with clinical benefit and well tolerated in drug-naïve patients with advanced refractory gastrointestinal stromal tumors. 2. This combination therapy achieved better global disease control and allowed...